President-elect Donald J. Trump’s proposals on tariffs, immigration, taxes and deregulation may have far-reaching and contradictory effects, adding uncertainty to forecasts.
Category: Stocks and Bonds
-
Bracing for a Fed Pullback on Interest Rates
Wall Street sees the central bank cutting interest rates on Wednesday. But growing worries about inflation are adding to investor uncertainty about its policy agenda for 2025.
-
High on Hope, Wall St. Hears What It Wants From Trump
Investors and executives are often emphasizing what they like in the president-elect’s agenda, while dismissing what they don’t as mere posturing.
-
The Fed Is Stuck Fighting the Last War
Mired in a battle to contain surging prices, the central bank also needs to be nimble enough for the economic downturns to come, our columnist says.
-
Macy’s Earnings Report Details Multimillion-Dollar Accounting Error
Analysts see much bigger challenges for the retailer than lax accounting.
-
Macy’s Details Multimillion-Dollar Accounting Error in Downbeat Report
Analysts see much bigger challenges for the retailer than lax accounting.
-
Wall Street’s Titans Can’t Wait for Trump 2.0
The financial world sees plenty of opportunity in the return of President-elect Donald J. Trump. For now, Wall Streeters are looking past the risks.
-
BlackRock Acquires HPS, a Major Lender of Private Credit
The world’s largest investor is buying HPS, a major provider of private credit, for $12 billion.
-
Elon Musk’s $50 Billion Tesla Pay Can’t Be Reinstated, Delaware Judge Rules
The judge said she would not reverse her decision to strike down the compensation package after Tesla shareholders approved Mr. Musk’s pay a second time.
-
Stocks Resume Post-Election Rise
With Friday’s gains included, November was the best month in a year for the S&P 500.
-
Will the Markets Check Trump’s Power?
The president-elect cares about financial markets, our columnist says. That gives investors a restraint on his decisions, even if it’s a tenuous one.
-
Drug Companies Face Hostility as They Hope for Allies Among Trump’s Health Picks
Robert F. Kennedy Jr. and other candidates for top health posts are at odds with the drug industry, setting the stage for tense battles over regulatory changes.